ZARXIO 300 MCG/0.5 ML SYRINGE
FDA nonproprietary name: filgrastim-sndz
For 0.5 mL
Pharmacies pay
$265.83 filed
0.5 × $531.655 per ML
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$263.38 filed
0.5 × $526.75682 per ML, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.99× estimated
Medicare paid about what pharmacies pay.
Part D averages every strength and form sold under “Zarxio” / “Filgrastim-Sndz” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$310.70 estimated
$265.83 + $39.87 (15%) + $5.00 fee per fill = $310.70
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
ZARXIO 300 MCG/0.5 ML SYRINGE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as filgrastim-sndz, under the trade name “ZARXIO”.
FDA gives its dosage form as injection, solution and its route as intravenous; subcutaneous.
The labeler, the company named on the label, is Sandoz Inc.
FDA’s Established Pharmacologic Class for it is Leukocyte Growth Factor.
The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.
NADAC classes it in its brand rate-setting class B-BIO, and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $265.83 for 0.5 mL (0.5 × $531.655 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
What NADAC measures · NADAC explanation codes
All 2 NDCs
- 61314-0318-01 · Sandoz Inc. · $531.655 per ML · eff. 2026-09-23 filed
- 61314-0318-05 · not listed as a package in the FDA directory · $531.655 per ML · eff. 2026-09-23 filed
Other strengths, forms and brands
1 other product in the NADAC file shares the FDA nonproprietary name filgrastim-sndz with ZARXIO 300 MCG/0.5 ML SYRINGE.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| ZARXIO 300 MCG/0.5 ML SYRINGE this page | $531.655 per ML filed | $526.75682 per ML filed |
| ZARXIO 480 MCG/0.8 ML SYRINGE | $533.4125 per ML filed | $526.75682 per ML filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-12-17, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
Compared with its class
The middle of its 2 NDCs’ NADAC prices is $531.655 per ML filed.
Of the 4 other products in FDA’s Leukocyte Growth Factor class priced per ML, 3 have a higher middle NADAC price and 1 a lower one. The one in the middle is ZARXIO 480 MCG/0.8 ML SYRINGE, at $533.4125 per ML filed (eff. 2025-12-17).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-12-17, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $263.38 for 0.5 mL, at an average of $526.75682 per ML in 2024 (2024-01-01 to 2024-12-31) for “Zarxio” and “Filgrastim-Sndz”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 24,638 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 0.5 mL? Is it lower than what I would pay through my insurance?
- How much is in the package I am getting? This page uses 0.5 mL; your package may hold a different amount.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for ZARXIO 300 MCG/0.5 ML SYRINGE labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Zarxio / Filgrastim-Sndz: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
- Why does this page start at 0.5 mL?
- NADAC prices this product per ML. The FDA NDC Directory’s package description gives 0.5 mL in one package for the 1 of this product’s 2 NDCs it lists (“1 BLISTER PACK in 1 CARTON (61314-318-01) / 1 SYRINGE in 1 BLISTER PACK / .5 mL in 1 SYRINGE”), so the card starts at one package: 0.5 ML. Change it to match your prescription.